In hepatocellular carcinoma, the treatment of insulin-like growth factor 1 promoted CK2-mediated CLOCK S106 phosphorylation, which consequentially disrupts the CLOCK-BMAL1 heterodimer and suppresses the expression of its downstream genes [17]. The gene discussed is IGF1; the disease is hepatocellular carcinoma.